Navigation Links
New Acetadote® Formulation Now Available in the U.S.
Date:3/22/2011

NASHVILLE, Tenn., March 22, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that it has completed the U.S. launch of its new formulation of Acetadote® (acetylcysteine) Injection, the Company's product used to treat acetaminophen poisoning. The proprietary new formulation, which does not contain ethylene diamine tetracetic acid (EDTA) or any other stabilization or chelating agents, is now stocked at wholesalers serving hospitals across the country.

Acetadote is used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter pain relief and fever-reducing products. The new formulation was approved by the U.S. Food and Drug Administration (FDA) in January and replaces the previously marketed product. Acetaminophen continues to be the leading cause of poisonings reported by hospital emergency rooms in the United States(1), and Acetadote has become a standard of care for treating this potentially life-threatening condition.

"We are pleased to make this next generation of Acetadote available to the hospital community and the growing number of patients who will benefit from it," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "This launch marks an important milestone in our strategy to support our products by improving upon existing formulations and expanding into new patient populations."

Cumberland has worked with U.S. wholesalers to transition inventories from the original to the new formulation. Shipments of the original formulation have ceased and the Company is now filling all Acetadote orders with the new product. A communications campaign has been initiated to support poison control centers and U.S. hospital pharmacists as they transition to the new formulation, which includes an extended shelf life of 30 months, up from 24 months for the o
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
3. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
4. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
7. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
8. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
9. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
10. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
11. New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... 2014   NuVascular Technologies, Inc. is ... medical devices that help millions. ... cutting-edge nanotechnology that would target serious conditions such ... The platform technology was developed over a ... in funding obtained from National Institutes of Health. ...
(Date:10/16/2014)... Oct. 16, 2014 Ninety percent of children ... relapsed multiple times or failed to respond to standard ... cellular therapy, CTL019, developed at the Perelman School of ... today in The New England Journal ... builds on preliminary findings presented at the American Society ...
(Date:10/16/2014)... Oct. 16, 2014   Reliant Renal Care, Inc. ... Home Choice TM Training Center at 650 ... passing all regulatory requirements without any deficiencies, our state-of- ... admitting patients. The Center focuses on the unique needs ... in the comfort of their home. The open-access facility ...
Breaking Medicine Technology:Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6A New Choice For Dialysis Patients In Bessemer 2
(Date:10/18/2014)... Dwight D. Im, M.D., FACOG, Director ... The National Institute of Robotic Surgery at Mercy ... world to successfully perform a minimally-invasive hysterectomy via ... Driver, developed by Intuitive Surgical, Inc. (ISRG). , ... and Drug Administration (FDA) clearance for use in ...
(Date:10/18/2014)... Recently, BamboofloorChina.com, one of the most distinguished bamboo ... assortment of bamboo floorings to its website. For ... worldwide clients now, up to 29 percent off. , ... for sale now; most of the company’s experts have been ... than 100 different kinds of elegant bamboo products on its ...
(Date:10/18/2014)... of Neuropsychopharmacology (ECNP) is pleased to announce that the ... Swaab, for his book, We are our Brains: From ... Media Award recognises outstanding contributions to destigmatising disorders of ... € 5,000. , The ECNP Media Award was established ... better understanding of the complexity and impact of disorders ...
(Date:10/18/2014)... One major trend upcoming in this ... which are making efforts to encourage people to donate ... organ donation process more transparent and easy. , Analysts ... to grow at a CAGR of 16.85 percent over ... the major drivers in the market is an increase ...
(Date:10/18/2014)... For the second time in less than a month, ... facing US businesses. On September 23rd, the warning ... employees. And now, according to this Reuters report , ... for US businesses about possible cyber espionage attacks by a ... high-value information.” , “With the constant stream of headlines ...
Breaking Medicine News(10 mins):Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 2Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 3Health News:Brand New Bamboo Floorings Now Unveiled By BamboofloorChina.com, A Distinguished Supplier In The Market 2Health News:Dick Swaab wins the 2014 ECNP Media Award 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Another FBI Cyber Attack Warning for US Businesses 2Health News:Another FBI Cyber Attack Warning for US Businesses 3Health News:Another FBI Cyber Attack Warning for US Businesses 4
... Phase II for melanoma, to begin Phase II for breast ... cancer ... today at 9:00 a.m. EDT -, BRANFORD, Conn., April 22 CuraGen Corporation,(Nasdaq: ... the quarter ended March 31, 2008, CuraGen reported a net loss,of $6.8 million, or ...
... China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical,Group (NYSE: ... of,branded generic pharmaceuticals and manufacturer of the ... announced that it has,signed a definitive agreement ... Wuhu,Zhong Ren Pharmaceutical Co. Ltd. for a ...
... for the Service,Employees International Union claimed in an ... other acts of intimidation against,officers, directors and staff ... nothing more than "free speech.", A temporary ... Court Commission Jon Rantzman remains in effect today. ...
... treatment with drug 5-fluorouracil, study says , , MONDAY, April ... used chemotherapy drug causes memory problems and other cognitive ... brain," a new study found. , Up to 50 ... problems a year after chemotherapy treatment ended, according to ...
... DANVILLE, PA. Hearing repeated stories of suffering from ... workers, a new Geisinger-led study suggests. , In a ... Social Work Practice, Geisinger Senior Investigator Joseph Boscarino, PhD, ... and secondary trauma among 236 New York City social ...
... Appointed to Board ... of Directors, CINCINNATI, April 21, 2008 ... (Jack) F. Smith (70),will retire from the board following P&G,s April board meeting ... to:, http://www.prnewswire.com/mnr/pg/32757/ Mr. Smith has served on the board since 1995 ...
Cached Medicine News:Health News:CuraGen Reports First Quarter 2008 Financial Results 2Health News:CuraGen Reports First Quarter 2008 Financial Results 3Health News:CuraGen Reports First Quarter 2008 Financial Results 4Health News:CuraGen Reports First Quarter 2008 Financial Results 5Health News:CuraGen Reports First Quarter 2008 Financial Results 6Health News:Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd. 2Health News:SEIU Claims Right of 'Free Speech' to Stalk, Harass, and Threaten Registered Nurses According to the California Nurses Association 2Health News:Common Chemotherapy Drug Linked to Memory Problems 2Health News:Common Chemotherapy Drug Linked to Memory Problems 3Health News:Procter & Gamble Announces Board Changes 2
Button shape tip, round serrated handle, dull finish, overall length 130 mm....
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: